Electronic Consent at US Cancer Centers: A Survey of Practices, Challenges, and Opportunities
JCO Clinical Cancer Informatics · 2023
DOI: 10.1200/cci.22.00122 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Clinical Cancer Informatics, 2023. Verfasst von Susan Chimonas und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Telemedicine, Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Digital technologies create opportunities for improving consenting processes in cancer care and research. Yet, little is known about the prevalence of electronic consenting, or e-consent, at US cancer care institutions. METHODS We surveyed institutions in the National Comprehensive Cancer Network about their capabilities for clinical, research, and administrative e-consents; technologies used; telemedicine consents; multilingual support; evaluations; and opportunities and challenges in moving from paper-based to electronic processes. Responses were summarized across responding institutions. RESULTS Twenty-five institutions completed the survey (81% response rate). Respondents were from all census regions and included freestanding and matrix cancer centers. Twenty (80%) had e-consent capabilities, with variability in the extent of adoption: One (5%) had implemented e-consent for all clinical, research, and administrative needs while 19 (95%) had a mix of paper and electronic consenting. Among those with e-consent capabilities, the majority (14 of 20, 70%) were using features embedded in their electronic health record. Most had a combination of paper and e-consenting for clinical purposes (18, 72%). About two-thirds relied entirely on paper for research consents (16, 64%) but had at least some electronic processes for administrative consents (15, 60%). Obstacles to e-consenting included challenges with procuring or maintaining hardware, content management, workflow integration, and digital literacy of patients. Successes included positive user experiences, workflow improvements, and better record-keeping. Only two of 20 (10%) respondents with e-consent capabilities had evaluated the impact of automating consent processes. CONCLUSION E-consent was prevalent in our sample, with 80% of institutions reporting at least some capabilities. Further progress is needed for the benefits of e-consenting to be realized broadly.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
- Digital Informatics and Technology Solutions, Memorial Sloan Kettering Cancer Center, New York, NY.
ORCID-Profile: Susan Chimonas, Allison Lipitz-Snyderman, Gilad J Kuperman
Förderung
- NCI NIH HHS
Zitieren
APA
Chimonas, S., Lipitz-Snyderman, A., Gaffney, K., & Kuperman, G. J. (2023). Electronic Consent at US Cancer Centers: A Survey of Practices, Challenges, and Opportunities. JCO Clinical Cancer Informatics. https://doi.org/10.1200/cci.22.00122
Vancouver
Chimonas S, Lipitz-Snyderman A, Gaffney K, Kuperman GJ. Electronic Consent at US Cancer Centers: A Survey of Practices, Challenges, and Opportunities. JCO Clinical Cancer Informatics. 2023. doi:10.1200/cci.22.00122
BibTeX
@article{Chimonas2023,
author = {Chimonas, Susan and Lipitz-Snyderman, Allison and Gaffney, Kemi and Kuperman, Gilad J},
title = {Electronic Consent at US Cancer Centers: A Survey of Practices, Challenges, and Opportunities},
journal = {JCO Clinical Cancer Informatics},
year = {2023},
doi = {10.1200/cci.22.00122}
}
EUVIMED